AVE 0309
Alternative Names: M 810309Latest Information Update: 03 Jul 2007
At a glance
- Originator Aventis Pharmaceuticals; OSI Pharmaceuticals
- Developer Aventis Pharmaceuticals
- Class Antiasthmatics
- Mechanism of Action Interleukin 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 03 Jul 2007 Discontinued - Phase-I for Asthma in USA (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 13 Jun 2002 Phase-I clinical trials in Asthma in USA (unspecified route)